Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Joincare Pharmaceutical Group Industry Co EBITDA Margin % Related Terms
Joincare Pharmaceutical Group Industry Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co EBITDA Margin % Chart
Joincare Pharmaceutical Group Industry Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a EBITDA Margin % of 28.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. This is near median its historical median of 26.00. Over the past decade, Joincare Pharmaceutical Group Industry Co's EBITDA Margin % has ranged from 19.30 to 61.27. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #243 out of 958 companies in the Drug Manufacturers industry, placing it in the top 25.4%.
Is Joincare Pharmaceutical Group Industry Co's EBITDA Margin % too high?
Joincare Pharmaceutical Group Industry Co's current EBITDA Margin % of 28.28% is near median its 10-year median of 26.00. Over the past 10 years, this metric has ranged from a low of 19.30 to a high of 61.27. The Drug Manufacturers industry median EBITDA Margin % is 11.93. Joincare Pharmaceutical Group Industry Co's value of 28.28% is 137% above this industry median. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #243 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #243 out of 958 companies for EBITDA Margin %. This puts Joincare Pharmaceutical Group Industry Co in the upper half of its industry. The industry median EBITDA Margin % is 11.93. Joincare Pharmaceutical Group Industry Co's value of 28.28% is 137% above this benchmark. Historically, Joincare Pharmaceutical Group Industry Co's own EBITDA Margin % has ranged from 19.30 to 61.27 over the past decade. While the company's 10-year median is 26.00 vs. the industry median of 11.93, Joincare Pharmaceutical Group Industry Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.93, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joincare Pharmaceutical Group Industry Co's current EBITDA Margin % of 28.28% is 137% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current EBITDA Margin % is 28.28%, which is near median its own 10-year median of 26.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a current EBITDA Margin % of 28.28%. The stock's GF Value™ is $9.20, compared to a current price of $8.00 — trading 13% below its estimated fair value. The current EBITDA Margin % is 28.28%, which is near median its 10-year median of 26.00 and 137% above the Drug Manufacturers industry median of 11.93. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (XSWX:JCARE), the current EBITDA Margin % is 28.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of $8.00 is trading 13% below its estimated GF Value™ of $9.20.
Key valuation signals for XSWX:JCARE:
EBITDA Margin %: 28.28% (near median its 10-year median of 26.00)
GF Value™: $9.20 vs. price of $8.00 (13% below fair value)
Industry Position: 137% above the Drug Manufacturers median (#243 of 958)
No single metric tells the full story. See the XSWX:JCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for XSWX:JCARE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JCARE has been successfully added to your 
